Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) – Stock analysts at Wedbush lifted their Q3 2024 EPS estimates for shares of Elevation Oncology in a report issued on Tuesday, August 6th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.20) per share for the quarter, up from their prior estimate of ($0.22). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.92) per share. Wedbush also issued estimates for Elevation Oncology’s Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.64) EPS.
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05.
View Our Latest Stock Analysis on Elevation Oncology
Elevation Oncology Price Performance
ELEV opened at $0.78 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 46.22 and a quick ratio of 46.22. The stock’s 50 day simple moving average is $2.71 and its 200 day simple moving average is $3.45. The firm has a market cap of $42.48 million, a price-to-earnings ratio of -0.75 and a beta of 1.38. Elevation Oncology has a 1 year low of $0.36 and a 1 year high of $5.83.
Institutional Trading of Elevation Oncology
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in Elevation Oncology during the 1st quarter valued at about $63,000. American Century Companies Inc. increased its position in shares of Elevation Oncology by 55.7% during the second quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock valued at $133,000 after acquiring an additional 17,602 shares in the last quarter. Rhumbline Advisers purchased a new position in Elevation Oncology in the 2nd quarter worth approximately $175,000. Bank of New York Mellon Corp bought a new position in Elevation Oncology in the 2nd quarter valued at approximately $415,000. Finally, Affinity Asset Advisors LLC purchased a new stake in Elevation Oncology during the 1st quarter valued at $6,509,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.
About Elevation Oncology
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
See Also
- Five stocks we like better than Elevation Oncology
- How to Invest in Blue Chip Stocks
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- How is Compound Interest Calculated?
- MarketBeat Week in Review – 8/5 – 8/9
- What is a Stock Market Index and How Do You Use Them?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.